Please assess the completion status of the following clinical trial:

Trial Title: PROACT - Pre-Operative Arimidex Compared To Tamoxifen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Operable or potentially operable breast cancer~* Invasive breast cancer proven to be hormone-sensitive (ER+/PR+)~* Patients who might benefit from endocrine treatment prior to surgery~* Postmenopausal~* Signed written informed consent~Exclusion Criteria:~* Inoperable breast cancer~* Patient unwilling to undergo surgery~* Any reason why the patient may not be able to conform to study requirements~* Any previous treatment for breast cancer~* Previous Tamoxifen use as a part of breast cancer prevention trials~* Not willing to stop taking drugs that affect sex-hormones such as HRT~* Previous history of breast cancer~* Previous history of invasive malignancy within the last 10 years~* Any other severe disease that may prevent surgery, place the patient at risk, or influence the study results~* Treatment with an experimental drug within the last 3 months~* Risk of transmitting HIV, Hepatitis B or C

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).